• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    4/6/23 9:06:27 AM ET
    $ARDS
    $BIMI
    $EDAP
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Pharmaceuticals
    Health Care
    Get the next $ARDS alert in real time by email

    Gainers

    • VistaGen Therapeutics (NASDAQ:VTGN) stock moved upwards by 22.8% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $35.7 million.
    • Lucy Scientific Discovery (NASDAQ:LSDI) stock moved upwards by 14.69% to $1.17. The company's market cap stands at $19.1 million.
    • Sonida Senior Living (NYSE:SNDA) shares rose 13.79% to $8.0. The company's market cap stands at $55.3 million.
    • OncoCyte (NASDAQ:OCX) shares increased by 11.06% to $0.3. The company's market cap stands at $35.6 million. As per the press release, Q4 earnings came out 3 days ago.
    • Edap TMS (NASDAQ:EDAP) shares rose 10.04% to $11.5. The company's market cap stands at $415.6 million.
    • Science 37 Hldgs (NASDAQ:SNCE) shares rose 9.61% to $0.31. The market value of their outstanding shares is at $36.1 million.

    Losers

    • Scilex Holding (NASDAQ:SCLX) stock declined by 18.4% to $10.12 during Thursday's pre-market session. The company's market cap stands at $1.4 billion.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares decreased by 14.45% to $0.37. The market value of their outstanding shares is at $5.8 million. As per the news, the Q4 earnings report came out 4 days ago.
    • Vallon Pharmaceuticals (NASDAQ:VLON) shares declined by 11.37% to $0.39. The company's market cap stands at $5.2 million.
    • BIMI Intl Medical (NASDAQ:BIMI) stock decreased by 9.63% to $0.51. The company's market cap stands at $1.9 million.
    • Aridis Pharmaceuticals (NASDAQ:ARDS) stock fell 9.32% to $0.24. The company's market cap stands at $8.6 million.
    • HCW Biologics (NASDAQ:HCWB) stock decreased by 8.97% to $1.32. The market value of their outstanding shares is at $47.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARDS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARDS
    $BIMI
    $EDAP
    $HCWB

    CompanyDatePrice TargetRatingAnalyst
    Sonida Senior Living Inc.
    $SNDA
    1/9/2026Neutral
    Robert W. Baird
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    EDAP TMS S.A.
    $EDAP
    5/15/2025Overweight → Neutral
    Piper Sandler
    EDAP TMS S.A.
    $EDAP
    4/4/2025$2.00Buy → Hold
    Jefferies
    Oncocyte Corporation
    $OCX
    3/28/2025$5.00Buy
    Lake Street
    More analyst ratings

    $ARDS
    $BIMI
    $EDAP
    $HCWB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Horn David R.

    3 - EDAP TMS SA (0001041934) (Issuer)

    2/13/26 5:59:52 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Scilex Holding Co sold $13,215,896 worth of shares (15,965,541 units at $0.83), decreasing direct ownership by 7% to 213,766,229 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Reporting)

    1/14/26 8:04:02 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Annen Steven claimed ownership of 41,490 shares (SEC Form 3)

    3 - EDAP TMS SA (0001041934) (Issuer)

    1/14/26 4:05:55 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ARDS
    $BIMI
    $EDAP
    $HCWB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 46th Annual TD Cowen Healthcare Conference. Vistagen's President and Chief Executive Officer, Shawn Singh, will present a corporate overview on Monday, March 2, 2026, at 3:50 p.m. Eastern Time. A replay of the webcast will be archived and available following the event through the "Events" page in the "Investors" section of the Company's website at www.Vistagen.com. About Vistagen Vistagen (NASDAQ:VTGN) is a late clinical-stage biopharmaceutical com

    2/25/26 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonida to Participate in Citi's 2026 Global Property CEO Conference

    Sonida Senior Living, Inc. ("Sonida" or the "Company") (NYSE:SNDA), a leading owner, operator and investor in senior living communities, announced today that Brandon Ribar, President & Chief Executive Officer, Kevin Detz, Chief Financial Officer and Max Levy, Chief Investment Officer, will participate in Citi's 2026 Global Property CEO Conference on Monday, March 2nd through Wednesday, March 4th at the Diplomat Resort & Spa Hollywood in Florida. Management will be available for one-on-one meetings with institutional investors during the conference. To schedule a meeting, please contact your bank representative. In addition, Mr. Ribar is scheduled to participate in a moderated roundtable

    2/25/26 8:15:00 AM ET
    $SNDA
    Hospital/Nursing Management
    Health Care

    TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

    BOSTON, Feb. 23, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy in the journal Molecular Imaging and Biology. The paper, published February 19, 2026, reports on a novel tumor-selective immunotherapy approach that activates innate immune signaling specifically within cancer cells while enabling non-invasive imaging of drug delivery. The study was carried out in collaboration with Dr. Anna Moore, Professor, Dire

    2/23/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $BIMI
    $EDAP
    $HCWB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Ribar Brandon bought $98,668 worth of shares (4,000 units at $24.67), increasing direct ownership by 1% to 327,176 units (SEC Form 4)

    4 - SONIDA SENIOR LIVING, INC. (0001043000) (Issuer)

    5/23/25 9:47:19 AM ET
    $SNDA
    Hospital/Nursing Management
    Health Care

    Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/20/25 4:35:35 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/20/25 4:35:07 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $BIMI
    $EDAP
    $HCWB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on Sonida Senior Living

    Robert W. Baird initiated coverage of Sonida Senior Living with a rating of Neutral

    1/9/26 9:07:37 AM ET
    $SNDA
    Hospital/Nursing Management
    Health Care

    VistaGen downgraded by Jefferies with a new price target

    Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90

    12/17/25 2:23:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Maxim Group

    Maxim Group downgraded VistaGen from Buy to Hold

    12/17/25 12:23:57 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $BIMI
    $EDAP
    $HCWB
    SEC Filings

    View All

    SEC Form 8-K filed by Sonida Senior Living Inc.

    8-K - SONIDA SENIOR LIVING, INC. (0001043000) (Filer)

    2/26/26 5:04:38 PM ET
    $SNDA
    Hospital/Nursing Management
    Health Care

    SEC Form 8-K filed by Sonida Senior Living Inc.

    8-K - SONIDA SENIOR LIVING, INC. (0001043000) (Filer)

    2/23/26 5:26:57 PM ET
    $SNDA
    Hospital/Nursing Management
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    2/23/26 8:10:39 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $BIMI
    $EDAP
    $HCWB
    Leadership Updates

    Live Leadership Updates

    View All

    EDAP Announces Appointment of David Horn to Board of Directors

             EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (NASDAQ:EDAP) ("the Company" or "EDAP"), a global leader in therapeutic ultrasound technology, today announced the appointment of David Horn to its Board of Directors, effective February 11, 2026. The addition of Mr. Horn strengthens the Board with extensive experience both advising and leading companies through periods of strategic growth and transformation. Mr. Horn will serve as a member of the Company's Audit Committee and Nominations Committee. "We are pleased to welcome David to the EDAP Board," said Lance Willsey, Chairman of the Board of EDAP. "David brings dee

    2/12/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

    PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company's litigation and intellectual property counsel. Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the C

    1/2/26 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDS
    $BIMI
    $EDAP
    $HCWB
    Financials

    Live finance-specific insights

    View All

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at

    2/4/26 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Datavault AI Inc. (NASDAQ: DVLT) Announces a Distribution Date of Dec. 24, 2025, for the Dream Bowl Meme Coin Tokens to All Eligible Record Equity Holders of Datavault AI and Holders of Common Stock of Scilex Holding Company

    PHILADELPHIA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- via IBN-- Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, and digital engagement technologies, today announced that its board of directors (the "Datavault Board") has set Dec. 24, 2025, as the distribution date for the Dream Bowl 2026 Meme Coin token (the "Meme Coin") to all eligible record equityholders of Datavault AI.  Dec. 24, 2025, will also be the distribution date for Datavault AI's voluntary distribution of Meme Coins to record holders of common stock of Scilex Holding Company (NASDAQ:SCLX), which is being made as a token of Datavault AI's appreciation for Scilex's relat

    12/11/25 4:05:00 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARDS
    $BIMI
    $EDAP
    $HCWB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

    SC 13G/A - Oncocyte Corp (0001642380) (Subject)

    12/9/24 5:30:06 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by HCW Biologics Inc.

    SC 13D/A - HCW Biologics Inc. (0001828673) (Subject)

    11/22/24 4:53:35 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 5:05:41 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care